Abatacept

Drug Profile

Abatacept

Alternative Names: BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 17 Jul 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Medical Center Groningen; University of Michigan
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Lupus nephritis; Myositis; Sjogren's syndrome
  • Phase II Diffuse scleroderma; Nephrotic syndrome
  • Preclinical Inflammation
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Multiple sclerosis; Psoriasis; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 10 Jul 2017 Bristol-Myers Squibb withdraws prior to enrolment a phase III trial for Giant cell arteritis (Combination therapy) in USA, Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Estonia, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Serbia, Spain, Sweden, Switzerland and United Kingdom (NCT03192969)
  • 06 Jul 2017 Pooled efficacy and adverse events data from the PsA-I and PsA-II trials in Psoriatic arthritis released by Bristol-Myers Squibb
  • 01 Jul 2017 Launched for Psoriatic arthritis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top